Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).
about
Pregnancy-Associated Changes in Pharmacokinetics: A Systematic ReviewPregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trialPlacental transfer of darunavir in an ex vivo human cotyledon perfusion model.Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B.Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2Health needs of HIV-infected women in the United States: insights from the women living positive survey.Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2)Tenofovir rescue therapy in pregnant females with chronic hepatitis BPharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infantsPregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202Meconium Tenofovir Concentrations and Growth and Bone Outcomes in Prenatally Tenofovir Exposed HIV-Uninfected ChildrenModel Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infantsPharmacokinetic studies in infants using minimal-risk study designsPrediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models.Pharmacokinetics of tenofovir during pregnancy and postpartum.Population Pharmacokinetics of Tenofovir in HIV-1-Uninfected Members of Serodiscordant Couples and Effect of Dose Reporting Methods.Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.Obstetric Pharmacokinetic Dosing Studies are Urgently Needed.A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV.Chronic hepatitis B virus infection and pregnancy.Pharmaceutical characterization of novel tenofovir liposomal formulations for enhanced oral drug delivery: in vitro pharmaceutics and Caco-2 permeability investigationsAnticoagulating obese patients in the modern era.Pharmacokinetic optimization of antiretroviral therapy in pregnancy.Population pharmacokinetic analysis during the first 2 years of life: an overview.Basic obstetric pharmacology.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).NRTI backbone in HIV treatment: will it remain relevant?Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats.Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach.A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxisBritish HIV Association guidelines for the management of HIV infection in pregnant women 2012
P2860
Q28109657-1CE282CA-3C2F-423C-B551-40583033AEC8Q28483723-408F630D-3705-4FC0-9D19-D4BEE6223E0AQ34057304-AD491477-50A6-4475-9B53-6EC6C5D1483DQ34409132-7E1FAD98-6372-49BF-B07D-A60016E0B857Q34429204-07EAEA6C-D84B-4E32-94C6-550222471492Q34483505-D492F5C6-4FCC-466C-B180-8B07C71A184EQ34737231-8814A463-CB72-4ECA-B8D0-9EF3A03DD017Q34904319-1C07E1E5-DA12-4940-AEEB-D70695173884Q35005051-6F79B356-BCF7-4883-B503-7C2C519BC264Q35128259-0884B0DD-28E2-44DF-8D94-4747AEEEFFC7Q35598502-C73D357D-C50B-4740-856E-0B69DB5DC63AQ35689404-66636E52-B1B5-4CE1-9E1B-D0EB3A411E5EQ35908584-54D87906-430C-43B8-AA06-B93AAF618E08Q36070335-1881A885-9E47-48AF-B9C1-818599744915Q36188725-02D8E467-CCD5-437A-B996-A41E8F63EB18Q36333957-467AA132-5BAD-459D-8658-A8EECA0F1DDFQ36438116-518B47C0-0F7C-47E5-BD2E-283369558450Q36706781-A9CC1363-2418-4616-A93E-3BEFFEA22F68Q36888597-8A9153A5-26BD-4B83-9D25-0A4540638398Q37203867-947B2317-FA47-4521-AB5D-13178FBD3F74Q37210864-7FD170CA-D8AF-414B-B19C-740558FD6D29Q37283062-004BBC11-F72A-491D-9B14-2C5581B964B4Q37551251-32994C90-F893-4D48-928A-F259EB66D6C7Q37575742-2D8B9982-5D1C-4A80-9F43-7852699CC2C8Q37588728-11A9FDFF-161E-4844-BE3B-0D8232CEF5FBQ37613468-C4ED9192-DAE9-4597-8556-7E84BFCB5339Q37669191-BE77938C-D559-436B-9714-B66AAF4807B3Q37919151-AB32080B-4039-49FA-B06C-9964BBE99103Q38047214-51E0FFEC-1DC3-48E0-B613-76159C62BE97Q38062388-AB0B55C0-7F8B-42A2-B0E4-9463E0031FEDQ38256590-4B8240ED-2DDA-40D7-B3E3-593ECE85D1D6Q38325427-216BF67E-8653-41DB-8934-FEC73B95D4BFQ39533858-CBC9BFA0-58F8-43E0-AD6D-2074473A92A7Q43475720-02EB8A7A-DFC6-4891-BA93-0F7CE81543C6Q48035659-81347F11-46F1-4633-A99F-656617F14424Q48072950-4814C08B-6069-41B6-86FD-1DAE30A330BDQ56910156-6A355622-E87B-480D-B933-CFF58F85C83FQ57076282-B9A25FE6-9FDB-438B-8613-F2D33E22BDA8
P2860
Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Population pharmacokinetics of ...... d their neonates (ANRS 12109).
@en
Population pharmacokinetics of ...... gnant women and their neonates
@nl
type
label
Population pharmacokinetics of ...... d their neonates (ANRS 12109).
@en
Population pharmacokinetics of ...... gnant women and their neonates
@nl
prefLabel
Population pharmacokinetics of ...... d their neonates (ANRS 12109).
@en
Population pharmacokinetics of ...... gnant women and their neonates
@nl
P2093
P2860
P356
P1476
Population pharmacokinetics of ...... d their neonates (ANRS 12109).
@en
P2093
ANRS 12109
C Amani-Bosse
D K Ekouévi
E Nerrienet
J McIntyre
J-M Tréluyer
P2860
P2888
P304
P356
10.1038/CLPT.2008.201
P407
P577
2008-11-05T00:00:00Z
P5875
P6179
1008665565